von Willebrand disease (vWD), the most common inherited bleeding disorder in humans, results from abnormalities in the plasma clotting protein von Willebrand factor (vWF). Severe (type HI) vWD is autosomal recessive in inheritance and is associated with extremely low or undetectable vWF levels. We report a method designed to distinguish mRNA expression from the two vWF alleles by PCR analysis of peripheral blood platelet RNA using DNA sequence polymorphisms located within exons of the vWF gene. This approach was applied to a severe-vWD pedigree in which three of eight siblings are affected and the parents and additional siblings are clinically normal. Each parent was shown to carry a vWF allele that is silent at the mRNA level. Family members inheriting both abnormal alleles are affected with severe vWD, whereas individuals with only one abnormal allele are asymptomatic. The maternal and paternal silent alleles are identical at two coding sequence polymorphisms as well as an intron 40 variable number tandem repeat, suggesting a possible common origin. Given the frequencies of the two exon polymorphisms reported here, this analysis should be applicable to -70% of type I and type III vWD patients. This comparative DNA and RNA PCR-restriction fragment length polymorphism approach may also prove useful in identifying defects at the level of gene expression associated with other genetic disorders.
ABSTRACT
von Willebrand disease (vWD), the most common inherited bleeding disorder in humans, results from abnormalities in the plasma clotting protein von Willebrand factor (vWF). Severe (type HI) vWD is autosomal recessive in inheritance and is associated with extremely low or undetectable vWF levels. We report a method designed to distinguish mRNA expression from the two vWF alleles by PCR analysis of peripheral blood platelet RNA using DNA sequence polymorphisms located within exons of the vWF gene. This approach was applied to a severe-vWD pedigree in which three of eight siblings are affected and the parents and additional siblings are clinically normal. Each parent was shown to carry a vWF allele that is silent at the mRNA level. Family members inheriting both abnormal alleles are affected with severe vWD, whereas individuals with only one abnormal allele are asymptomatic. The maternal and paternal silent alleles are identical at two coding sequence polymorphisms as well as an intron 40 variable number tandem repeat, suggesting a possible common origin. Given the frequencies of the two exon polymorphisms reported here, this analysis should be applicable to -70% of type I and type III vWD patients. This comparative DNA and RNA PCR-restriction fragment length polymorphism approach may also prove useful in identifying defects at the level of gene expression associated with other genetic disorders.
von Willebrand factor (vWF) is a central component of hemostasis, serving as the carrier for factor VIII and as the adhesive link between platelets and blood vessel wall. Synthesis of vWF is limited to endothelial cells and megakaryocytes, where it is assembled from a 220-kDa monomer subunit into multimers ranging up to 20 MDa (1) . The human vWF gene spans 178 kilobases (kb) and contains 52 exons corresponding to an 8.7-kb mRNA (2-7). The vWF gene has been localized to the short arm of chromosome 12 (2) , and an unprocessed pseudogene comprising the middle third of the gene has been mapped to chromosome 22 (8) .
Abnormalities of vWF result in von Willebrand disease (vWD), the most common inherited bleeding disorder in humans; estimated prevalence is as high as 1% (9) . Type I vWD, accounting for 70-80% of cases, is characterized by a quantitative defect in vWF and is autosomal dominant in inheritance. The reduced penetrance and limited sensitivity of currently available diagnostic tests may leave many cases undiagnosed (10) . Type III vWD denotes a severe form of the disease associated with major hemorrhagic symptoms and characterized by extremely low or undetectable levels of vWF (11) . The incidence of type III vWD has been estimated at -1 per million (12) (13) (14) . In some cases one or both parents have type I vWD, and the severe vWD appears a manifestation of homozygous (or compound heterozygous) type I. In other cases both parents are asymptomatic, and the apparent mode of inheritance is autosomal recessive (13) (14) (15) . Whether these patterns represent two distinct genetic disorders or rather manifestations of the broad spectrum and variable expressivity of type I vWD is currently unclear.
Until recently, little was known about the molecular defects responsible for vWD. Given the complex multistep biosynthesis and processing of vWF, defects at a number of loci outside of the vWF gene could conceivably result in similar vWD phenotypes. All genetic linkage studies in vWD to date, however, have been consistent with defects within the vWF gene (16) (17) (18) (19) (20) . In addition, missense mutations within the vWF gene have recently been reported in a qualitative variant of vWD, type IIA (21) . Although large gene deletions have been reported in several type III vWD families (8, 22, 23) , Southern blot analyses in the majority of vWD patients show no evidence for gross gene deletion or rearrangement at the vWF locus. Further analysis of the molecular basis for vWD in this large group of patients has been limited due to the large size ofthe vWF gene and the lack of a ready source of vWF mRNA.
We report a general method for detecting genetic defects at the level of vWF mRNA expression. Using DNA sequence polymorphisms located within exons of the vWF gene, expression from the two vWF alleles can be distinguished by RNA PCR analysis from peripheral blood platelets. By this approach we have identified the defective vWF allele in a pedigree with type III vWD. Family members inheriting two abnormal alleles are affected with severe vWD, whereas individuals with only one abnormal allele are asymptomatic. These methods should be applicable to the identification of defects at the level of mRNA in numerous genetic disorders.
MATERIALS AND METHODS
Patients. Twelve members of a three-generation type III vWD family were investigated (Fig. 1) $To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Preparation of Total Cellular RNA and Genomnc DNA. Platelet-rich plasma prepared from 40 ml of peripheral blood by centrifugation at 100 x g for 10 min was centrifuged at 2500 x g for 10 min to form a platelet pellet. Total RNA was prepared from this pellet, and high-molecular weight lymphocyte DNA was prepared from peripheral blood, both as described (21) .
PCR. DNA and RNA PCR reactions were done as described (21) . For RNA PCR, -1 ,ug of total platelet RNA was used as template for the reverse transcriptase reaction by using either oligonucleotide 1 or 4 as reverse transcriptase primer ( Table 2) followed by PCR amplification. One microgram of genomic DNA was used as template for DNA PCR. The technique of allele-specific PCR was used to selectively amplify the authentic vWF gene (24, 25) . Primer 3 was positioned such that the 3'-terminal nucleotide matches the sequence of the authentic vWF gene but differs from that of the vWF chromosome 22 pseudogene (M. Bruck and D.G., unpublished data).
Cloning and DNA Sequence Analysis. For analysis of the polymorphism at 4641, PCR products generated with primers 2 and 3 were digested with EcoRl and BamHI and directionally subcloned into M13mpl8 or M13mpl9. Independent M13 clones were sequenced with Sequenase, as described (21 The BstEII digestion products were transferred to Hybond-N nylon (Amersham) and probed with full-length vWF cDNA radiolabeled by hexamer priming (26) . After overnight hybridization in 6x standard saline phosphate EDTA (SSPE) (lx SSPE = 0.15 M NaCI/0.01 M NaH2PO4H2O/0.001 M EDTA, pH 7.4)/1% SDS and sheared salmon sperm DNA at 100 ng/ml at 68°C, the filter was washed to 0.05 x SSPE/0.1% (-) were detected for the 3' end of the VNTR and were arbitrarily A,-4/ (from largest to smallest) designated a-d; these four alleles were inherited in a Mendelian fashion by the family members. RNA PCR Studies. Although the three affected sisters (II-1, 11-2, and II-7) were homozygous for the two exonic poly-) morphisms, their father (I-1) and two brothers were heterozygous at both positions. PCR analysis of platelet mRNA revealed that while individual 11-5 expressed both the BstEII+ and the BstEII-alleles, individuals I-1 and II-3 in vWF mRNA expressed only the BstEII-allele (Fig. 3) . DNA (2, 8, 16-19, 22, 23) . Further characterization of the molecular defect(s) responsible for vWD has been difficult, given the large size and complexity of the vWF gene, the presence of a partial unprocessed pseudogene, and the lack of a readily available source of patient vWF mRNA. The advent of the PCR enabled detection of missense mutations at the vWF locus in association with type HAvO , aided by the localization of these mutations within a discrete region of vWF (21 Comparative DNA and mRNA PCR-RFLP analysis, as described here, should also be applicable to a number ofother genetic disorders. Indeed, the use of RNA PCR has resulted in the fortuitous detection of silent alleles at both the insulin receptor locus and the branched chain a-ketoacid dehydrogenase locus by comparison with missense mutations on the opposite allele in compound heterozygotes (31, 32) . Using a panel of PCR-RFLPs, our approach should be useful for a large number of patients with diverse genetic diseases.
As noted above, the polymorphism at position 4641 resulted in inadvertent allele-specific PCR initially interpreted incorrectly as loss of mRNA expression (21) . Although allele-specific PCR can be successfully achieved by using primers with single-base mismatches positioned at the critical 3' nucleotide (24, 25) (33) (34) (35) (36) . Given (8, 14, 15, 22, 23, 30, 37) . Given the low penetrance of vWD and the contribution of other factors, such as blood type and estrogen levels to phenotypic expression (10, 38) , it is not clear that type III vWD can truly be distinguished from homozygous type I vWD. Type III vWD may be a heterogeneous disorder resulting from homozygosity (or compound heterozygosity) for a wide range of abnormal vWF alleles, including very mild or asymptomatic type I alleles and potentially mild qualitatively abnormal (type II) alleles. Heterozygosity for silent alleles, as identified here, might account for many of these asymptomatic type I alleles, whereas mutations giving rise to abnormal vWF, which interfere with multimer expression from the normal allele [dominant negative mutations (39)], might be responsible for the majority of symptomatic type I vWD alleles.
If a feedback mechanism exists for regulation of total cellular vWF mRNA, this could account for a high frequency of asymptomatic carriers among patients with silent alleles. In the homozygous individual, lack of expression from both alleles would result in severe vWD, whereas in the heterozygous individual, loss of RNA from the defective allele would trigger a compensatory increase in expression from the remaining normal allele, resulting in an asymptomatic or carrier phenotype. No such compensation would occur in vWF defects associated with stable mRNAs and would result in intermediate symptoms in heterozygotes, manifest as type I vWD. Such a mechanism could help explain the broad range of clinical severity among type I and type III vWD patients. Consistent with this hypothesis, the reported vWF gene deletions associated with severe vWD, which would also result in loss of mRNA expression from the defective allele, have been associated with a silent phenotype in the obligate heterozygotes. In preliminary studies from our laboratory, loss of expression from one allele has been observed in a second type III family with expression from both alleles observed in three type I patients.
Over the past several years, considerable progress has been made in our understanding of the structure and function of vWF and the molecular basis of vWD. A clearer picture of the phenotypic heterogeneity is beginning to emerge as the molecular defects responsible for distinct vWD variants are defined. With continued progress, it may eventually become possible to provide rapid and accurate DNA-based diagnosis and classification for this common and complex bleeding disorder.
